Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01491971 · ClinicalTrials.gov registry record · Phase 2
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 15
- Study locations
NCT01491971: Completed Phase 2 study of Prostate Cancer, sponsored by Ferring Pharmaceuticals.
NCT01491971 is a Phase 2 study of Prostate Cancer that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 76 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01491971, a Phase 2 study of Prostate Cancer, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 15
- Study locations
Study Summary
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer.
Conditions Studied
Interventions
- DRUG Degarelix
Study Locations (15)
Ontario
- Euroscope Inc - Barrie
- Bramalea Medical Centre - Brampton
- Urology Associates/Urologic Medical Research - Kitchener
- Office of Dr. Bernard Goldfarb - North Bay
California
- South Orange County Urology Research - Laguna Hills
- San Bernadino Urological Association - San Bernadino
Texas
- Urology Clinic of North Texas - Dallas
- Urology San Antonio Research, Pa - San Antonio
Alabama
- Urology Centers of Alabama - Homewood
Florida
- South Florida Medical Research - Aventura
New York
- Premier Medical Group of the Hudson Valley - Poughkeepsie
North Carolina
- Carolina Clinical Trials - Concord
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
What the finished NCT01491971 record still lists
NCT01491971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Degarelix is the first listed.
NCT01491971 lists 15 locations in 10 states (Ontario, California, Texas).
Frequently Asked Questions
What is clinical trial NCT01491971 about?
NCT01491971 is a clinical study titled "Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer". Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer.
What is the current status of trial NCT01491971?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2012-01. Estimated completion is 2012-11.
What conditions does trial NCT01491971 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01491971?
The interventions under investigation include: Degarelix (DRUG).
Who is sponsoring clinical trial NCT01491971?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01491971 being conducted?
This trial has 15 study locations across Alabama, California, Florida, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01491971's enrollment target sits among peer trials
76 388th of 735 higher than 345 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia